Select Language
LRRC32 & Latent TGF-beta 3
Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dutogliptin Tartrate | REC-01; PHX-1149; PHX-1149T | Phase 3 Clinical | Phenomix | ST Elevation Myocardial Infarction; Myocardial Infarction; Diabetes Mellitus, Type 2; Kidney Diseases; Leukemia, Myeloid, Acute | Details |
| Yogliptin | Phase 3 Clinical | Sichuan Sunheal Pharmaceutical Co Ltd, Chengdu Easton Biopharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| CPL2009-0031 | Phase 3 Clinical | Cadila Healthcare Ltd | Diabetes Mellitus, Type 2 | Details | |
| Dapagliflozin formate/Linagliptin | IN-C009; AJU-A51 | Phase 3 Clinical | HK inno.N Corporation, Aju Pharm Co Ltd | Diabetes Mellitus, Type 2 | Details |
| DA5221-B2 | DA5221-B2 | Phase 3 Clinical | Dong-A ST Co Ltd | Diabetes Mellitus, Type 2 | Details |
| LID104 | LID104; LID-104 | Phase 3 Clinical | Ems | Diabetes Mellitus, Type 2 | Details |
| TOTUM•63 | TOTUM-63 | Phase 3 Clinical | Valbiotis | Diabetes Mellitus, Type 2 | Details |
| Dapagliflozin/Sitagliptin | SID-1903; DW-6012 | Phase 3 Clinical | Astrazeneca Sa | Diabetes Mellitus, Type 2; ST Elevation Myocardial Infarction; Myocardial Infarction | Details |
| Talabostat | PT-100; BXCL-701 | Phase 2 Clinical | Point Therapeutics | Neuroblastoma; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Germ Cell and Embryonal; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Leukemia, Myeloid, Acute; Prostatic Neoplasms; Liver Neoplasms; Brain Neoplasms; Sarcoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
| TQ-F3083 | TQ-F3083; CT-383 | Phase 2 Clinical | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details | |
| Begelomab | SAND-26; BT 5/9 | Phase 2 Clinical | Adienne | Dermatomyositis; Graft vs Host Disease | Details |
| YS-110 | YSCMA; YS-110 | Phase 2 Clinical | Y'S Therapeutics Inc | Mesothelioma | Details |
| Singletine | DC-291407; DC-407; DC291407 | Phase 2 Clinical | Cisen Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2; Fatty Liver | Details |
| GCP-002 | EP-HMRG | Phase 2 Clinical | Esophageal Neoplasms | Details | |
| Metformin/Dapagliflozin/Sitagliptin | GMRx4 | Phase 2 Clinical | George Medicines PTY Ltd, George Medicines UK Ltd | Diabetes Mellitus, Type 2 | Details |
| Bogliptin maleate | HL012MA | Phase 2 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, East China University Of Science And Technology, Shandong Baiji Dichang Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Augliptin Hydrochloride | Phase 1 Clinical | Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd, Nanjing Changao Pharmaceutical Science And Technologyco Ltd | Diabetes Mellitus, Type 2 | Details | |
| Evogliptin Tartrate | LY-05007 | Phase 1 Clinical | Dong-A Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| TQ-05510 | TQ-05510 | Phase 1 Clinical | Diabetes Mellitus, Type 2 | Details | |
| Lobeglitazone/Sitagliptin | CKD-396 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Telmisartan | HDDO-16091 + HDDO-16092; HOB-077; HDDO-1609 | Phase 1 Clinical | Hyundai Pharmaceutical Co Ltd | Hypertension; Diabetes Mellitus | Details |
| TSL-0319 | TSL-0319 | Phase 1 Clinical | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Linagliptin/Fimasartan Potassium Trihydrate | Phase 1 Clinical | Boryung Pharmaceutical Co Ltd | Hypertension; Diabetes Mellitus | Details | |
| Retagliptin Phosphate/Metformin Hydrochloride | HRX-0701 | Phase 1 Clinical | Diabetes Mellitus, Type 2 | Details | |
| CGT-2201 | CGT-2201 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
| Empagliflozin/Metformin/Sitagliptin (Chong Kun Dang Pharmaceutical) | CKD-379 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Metformin/Sitagliptin (Overseas Pharmaceuticals) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| THDBH-100 | THDBH100; THDBH101 | Phase 1 Clinical | Wuxi Apptec(Shanghai) Co Ltd | Diabetes Mellitus, Type 2 | Details |
| WXSHC-071 | WXSHC-071 | Phase 1 Clinical | Dongbao Zixing (Hangzhou) Biological Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
| REC-04 | Clinical | Recardio Inc | Cardiovascular Diseases | Details | |
| Dutogliptin Tartrate/Metformin Hydrochloride | Phenomix Corporation | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemigliptin L-tartrate Sesquihydrate | LC-150444; LC-15-0444 | Approved | Lg Life Sciences Ltd | Gemiglo, Zemiglo | South Korea | Diabetes Mellitus, Type 2 | Lg Life Sciences Ltd | 2012-06-27 | Diabetes Mellitus, Type 2; Hepatic Insufficiency | Details |
| Gemigliptin L-tartrate Sesquihydrate/Metformin Hydrochloride | Approved | Lg Life Sciences Ltd | ZemiMet SR | South Korea | Diabetes Mellitus, Type 2 | Lg Life Sciences Ltd | 2015-01-01 | Diabetes Mellitus, Type 2 | Details | |
| Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride | Approved | Handok Inc | Tenelia M SR | South Korea | Diabetes Mellitus, Type 2 | Handok Inc | 2015-11-03 | Diabetes Mellitus, Type 2 | Details | |
| Evogliptin | DA-1229 | Approved | Dong-A Pharmaceutical Co Ltd | Suganon, Sugarnon | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-10-02 | Diabetes Mellitus, Type 2; Kidney Diseases; Aortic valve diseases; Liver Diseases | Details |
| Saxagliptin Hydrate | BMS-477118; BMS-477118-11; OPC-262 | Approved | Bristol-Myers Squibb Company | 安立泽, Onglyza | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2009-07-31 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details |
| Teneligliptin Hydrobromide Hydrate | MP-513 | Approved | Mitsubishi Tanabe Pharma | Tenelia, Tenglyn | Japan | Diabetes Mellitus, Type 2 | Mitsubishi Tanabe Pharma, Daiichi Sankyo Co Ltd | 2012-06-29 | Diabetes Mellitus, Type 2 | Details |
| Retagliptin Phosphate | SP-2086 Phosphate | Approved | 瑞泽唐 | Mainland China | Diabetes Mellitus, Type 2 | Jiangsu Hengrui Medicine Co Ltd | 2023-06-27 | Diabetes Mellitus, Type 2; Renal Insufficiency; Diabetes Mellitus | Details | |
| Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | MK-0431J | Approved | Merck & Co Inc, Astellas Pharma Inc | Sujanu | Japan | Diabetes Mellitus, Type 2 | null | 2018-03-23 | Diabetes Mellitus, Type 2 | Details |
| Linagliptin | BI-1356; BI-1356-BS | Approved | Boehringer Ingelheim Gmbh | 欧唐宁, Ondero, Trajenta, Trayenta, Trazenta, Tradjenta | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2011-05-02 | Prediabetic State; Diabetes Mellitus, Type 2; Albuminuria; Renal Insufficiency; Schizophrenia; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Hypertension; Endocrine System Diseases; Coronavirus Infections; Metabolic Diseases; Hepatic Insufficiency; Glucose Metabolism Disorders; Inflammation; Diabetes Mellitus; Ventricular Dysfunction, Left | Details |
| Rosuvastatin Calcium/Gemigliptin L-tartrate Sesquihydrate | Approved | Lg Life Sciences Ltd | ZemiStatin | Diabetes Mellitus, Type 2; Dyslipidemias | Details | |||||
| Alogliptin Benzoate | SYR-322; TAK-322 | Approved | Takeda | Nesina, 尼欣那, Vipidia | Japan | Diabetes Mellitus, Type 2 | Takeda | 2010-04-06 | Diabetes Mellitus, Type 2; Acute Coronary Syndrome; Diabetes Mellitus | Details |
| Empagliflozin/Linagliptin/Metformin | Approved | Boehringer Ingelheim Gmbh, Eli Lilly And Company | Trijardy XR | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2020-01-27 | Diabetes Mellitus, Type 2 | Details | |
| Sitagliptin Phosphate/Metformin Hydrochloride | Approved | Merck & Co Inc | Velmetia, Janumet, 捷诺达, Zituvimet | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2007-03-30 | Diabetes Mellitus, Type 2 | Details | |
| Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate | Approved | Mitsubishi Tanabe Pharma Corp, Daiichi Sankyo Co Ltd | Canalia | Japan | Diabetes Mellitus, Type 2 | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma | 2017-07-03 | Diabetes Mellitus, Type 2 | Details | |
| Anagliptin/Metformin Hydrochloride | SK-1501 | Approved | Sanwa Kagaku Kenkyusho Co Ltd, Suzuken | Metoana | Japan | Diabetes Mellitus, Type 2 | Sanwa Kagaku Kenkyusho Co Ltd | 2018-09-21 | Diabetes Mellitus, Type 2 | Details |
| Vildagliptin/Metformin Hydrochloride | LMF-237 | Approved | Novartis Pharma Ag | 宜合瑞, Eucreas, EquMet, Zomarist, Icandra | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-11-14 | Diabetes Mellitus, Type 2 | Details |
| Cetagliptin Phosphate | CGT-8012 | Approved | Cgenetech(Suzhou China) Co Ltd | 盛捷维 | Mainland China | Diabetes Mellitus, Type 2 | Cgenetech(Suzhou China) Co Ltd | 2024-12-01 | Diabetes Mellitus, Type 2 | Details |
| Alogliptin Benzoate/Metformin Hydrochloride | CT-L01; CT-L-01 | Approved | Takeda Pharmaceutical Co Ltd | Vipdomet, Inisync, Kazano | United States | Diabetes Mellitus, Type 2 | Takeda Pharmaceuticals U.S.A. Inc | 2013-01-25 | Diabetes Mellitus, Type 2 | Details |
| Cofrogliptin | HSK7653; HSK-7653 | Approved | Liaoning Haisco Pharmaceutical Co Ltd, Sichuan Haisco Pharmaceutical Co Ltd | 倍长平 | Mainland China | Diabetes Mellitus, Type 2 | Haisco Pharmaceutical Group Co Ltd | 2024-06-18 | Diabetes Mellitus, Type 2; Renal Insufficiency; Glucose Intolerance | Details |
| Anagliptin | SK-0403; CWP-0403 | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Suiny, Beskoa | Japan | Diabetes Mellitus, Type 2 | null | 2012-09-28 | Diabetes Mellitus, Type 2 | Details |
| Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride | Approved | Astrazeneca Plc | Qtern | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2016-07-15 | Diabetes Mellitus, Type 2 | Details | |
| Alogliptin Benzoate/Pioglitazone Hydrochloride | SYR-322-4833 BL | Approved | Takeda Pharmaceutical Co Ltd | Nesinaact, Oseni, Liovel, Incresync | Japan | Diabetes Mellitus, Type 2 | Takeda | 2011-07-01 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin Phosphate Monohydrate | ONO-5435A; ONO-5435; MK-0431; MK-431; L-000224715 | Approved | Merck Sharp & Dohme Corp | Ristaben, Xelevia, Tesavel, Glactiv, 捷诺维, Januvia, DIABIT-IS X | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2006-10-16 | Myelodysplastic Syndromes; Hyperlipidemias; Kidney Failure, Chronic; Carcinoma, Hepatocellular; Diabetes Mellitus; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Renal Insufficiency, Chronic; Inflammation; Hepatitis C; Hepatic Insufficiency; Cardiovascular Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Gastroparesis; HIV Infections; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Glucose Intolerance; Insulin Resistance; Atherosclerosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Heart Failure; Leukemia, Myelogenous, Chronic; Cystic Fibrosis; Prediabetic State; Diabetes Mellitus, Type 1 | Details |
| Trelagliptin Succinate | TAK-472; SYR-472; SYR-111472; SYR-111472 succinate | Approved | Takeda Pharmaceutical Co Ltd | Zafatek | Japan | Diabetes Mellitus, Type 2 | Takeda | 2015-03-26 | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
| Evogliptin Tartrate/Metformin Hydrochloride | DA-1229_01 | Approved | Dong-A Pharmaceutical Co Ltd | Sugamet XR | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-12-01 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Ertugliflozin | Approved | Pfizer Inc | Steglujan | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2017-12-19 | Diabetes Mellitus, Type 2 | Details | |
| Omarigliptin | MK-3102 | Approved | Merck & Co Inc | Marizev | Japan | Diabetes Mellitus, Type 2 | Merck Sharp & Dohme Corp | 2015-09-28 | Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic; Diabetes Mellitus | Details |
| Teneligliptin/Pioglitazone | Approved | Glenmark Pharmaceuticals Ltd | Zita Plus Pio | India | Diabetes Mellitus, Type 2 | Glenmark Pharmaceuticals Ltd | 2022-04-25 | Diabetes Mellitus, Type 2 | Details | |
| Metformin Hydrochloride/Sitagliptin Hydrochloride | Approved | Sandoz Bv | EU | Sandoz Bv | 2019-12-10 | Diabetes Mellitus, Type 2 | Details | |||
| Sitagliptin Tartrate | Approved | Heumann Pharma GmbH & Co Generica KG | Sitagliptin Heumann 25 mg Filmtabletten | EU | Heumann Pharma GmbH & Co Generica KG | 2020-12-14 | Diabetes Mellitus, Type 1; Parkinson Disease; Diabetic Nephropathies | Details | ||
| Sitagliptin Hydrochloride | Approved | Laboratorios Alter Sa | Spain | Diabetes Mellitus, Type 2 | Laboratorios Alter Sa | 2019-03-06 | Diabetes Mellitus, Type 2; Polycystic Ovary Syndrome | Details | ||
| Gemigliptin | Approved | Details | ||||||||
| Linagliptin/Metformin Hydrochloride | GC2129A; GC-2129-A; DW6013 | Approved | Boehringer Ingelheim Gmbh | Jentadueto Xr, Trajenta Duo, Jentadueto, 欧双宁 | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2012-01-30 | Diabetes Mellitus, Type 2 | Details |
| Linagliptin/Empagliflozin | BI 1356/BI 10773; BI 10773/linagliptin; BI 1356/empagliflozin; Empagliflozin/BI 1356; Linagliptin/BI 10773; BI 10773/BI 1356 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Tradiance, Glyxambi, Esgliteo | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2015-01-30 | Diabetes Mellitus, Type 2; Cardiovascular Diseases | Details |
| Vildagliptin | LAF-237; DSP-7238; LAF-237A; NVP-LAF-237 | Approved | Novartis Pharma Ag | 佳维乐, Equa, Jalra, Galvus, Gliptus, Xiliarx | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-09-25 | Prediabetic State; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Renal Insufficiency; Schizophrenia; Kidney Diseases; Insulin Resistance; Dyslipidemias; Diabetes, Gestational; Diabetes Mellitus | Details |
| Saxagliptin Hydrochloride/Metformin Hydrochloride | Approved | Astrazeneca Plc | 安立格, Kombiglyze Xr, Komboglyze | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2010-11-05 | Diabetes Mellitus, Type 2 | Details |
- Product Inquiry
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland